Prolensa (Bromfenac Sodium) Patent Expiration, LOE Window & CMS Spending

Prolensa (Bromfenac Sodium) by Bausch Health: FDA Orange Book LOE 2033-11-11, 5 AB generics, $45.0M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBausch Health
FDA Application & PathwayN203168 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2033-11-11
Orange Book Patents (*PED Extensions)2 patents (0 *PED)
Active AB-Rated Generic Competitors5
2024 CMS Total Public Spend$45.0M
2024 Medicare Part D Spend$44.5M
2024 Medicaid Spend$584K
Reported Wholesale Price Change (CA SB 17)2 WAC filings (max 19.1% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bausch Health / Bausch + Lomb across sibling Meru public-data platforms.